The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
In the Lab Isabella Cueto When spinal fluid from ALS patients was put into mice, the mice got weak. An unlikely protein could be the culprit
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment
Biotech Adam Feuerstein Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections
Pharmalot Ed Silverman FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street
Biotech Adam Feuerstein Biogen drug for rare form of ALS fails pivotal study — another setback for fatal disease with few treatments
Biotech Adam Feuerstein Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval
Biotech Adam Feuerstein Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome
Health Priyanka Dayal McCluskey — Boston Globe For ALS patients robbed of speech, a new way of ‘speaking’